Titan Pharmaceuticals
TTNP
TTNP was delisted on the 1st of October, 2025.
20 hedge funds and large institutions have $759K invested in Titan Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 2 increasing their positions, 6 reducing their positions, and 3 closing their positions.
100% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 3
11% more funds holding
Funds holding: 18 → 20 (+2)
0.03% less ownership
Funds ownership: 0.36% → 0.33% (-0.03%)
33% less capital invested
Capital invested by funds: $1.14M → $759K (-$380K)
67% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
+$1.53K |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$321 |
| 3 |
Group One Trading
Chicago,
Illinois
|
+$284 |
| 4 |
PNC Financial Services Group
Pittsburgh,
Pennsylvania
|
+$189 |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$132 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FIA
FNY Investment Advisers
New York
|
-$30K |
| 2 |
Millennium Management
New York
|
-$19K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$14K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$10.4K |
| 5 |
Renaissance Technologies
New York
|
-$9.74K |
TTNP Hedge Fund Activity: Q4 2022 in Review
20 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Titan Pharmaceuticals (TTNP) for Q4 2022, worth a combined $759K — down 33% from $1.14M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new TTNP positions and 3 closed out — a net gain of 3 holders — while 2 added to existing stakes and 6 trimmed.
The largest buyer was Tower Research Capital (TRC), opening a new position worth an estimated $1.53K. The largest seller was FNY Investment Advisers, exiting entirely with an estimated $30K sold.
- 20 institutional investors held Titan Pharmaceuticals (TTNP) as of Q4 2022, up from 18 in Q3 2022.
- Funds reported $759K of Titan Pharmaceuticals stock for Q4 2022, down 33% quarter-over-quarter.
- 6 funds opened new Titan Pharmaceuticals positions in Q4 2022 and 3 closed out, a net change of +3 holders.
- The largest Titan Pharmaceuticals buyer in Q4 2022 was Tower Research Capital (TRC), an estimated $1.53K added.
- The largest Titan Pharmaceuticals seller in Q4 2022 was FNY Investment Advisers, an estimated $30K sold.
Based on aggregated 13F filings for Q4 2022.